Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials

Publication date: Available online 3 October 2017
Source:Journal of the American Academy of Dermatology
Author(s): Mark G. Lebwohl, Kim A. Papp, Lauren B. Marangell, John Koo, Andrew Blauvelt, Melinda Gooderham, Jashin J. Wu, Shipra Rastogi, Susan Harris, Radhakrishnan Pillai, Robert J. Israel
BackgroundIndividuals with psoriasis are at increased risk for psychiatric comorbidities, including suicidal ideation and behavior (SIB).ObjectiveTo distinguish between the underlying risk and potential for treatment-induced psychiatric adverse events in patients with psoriasis being treated with brodalumab, a fully human anti–interleukin 17 receptor A monoclonal antibody.MethodsData were evaluated from a placebo-controlled, phase 2 clinical trial; the open-label, long-term extension of the phase 2 clinical trial; and three phase 3, randomized, double-blind, controlled clinical trials (AMAGINE-1, AMAGINE-2, and AMAGINE-3) and their open-label, long-term extensions of patients with moderate-to-severe psoriasis.ResultsThe analysis included 4464 patients with 9161.8 patient-years of brodalumab exposure. The follow-up time–adjusted incidence rates of SIB events were comparable between the brodalumab and ustekinumab groups throughout the 52-week controlled phases (0.20 vs 0.60 per 100 patient-years). In the brodalumab group, 4 completed suicides were reported, 1 of which was later adjudicated as indeterminate; all patients had underlying psychiatric disorders or stressors.LimitationsThere was no comparator arm past week 52. Controlled study periods were not powered to detect differences in rare events such as suicide.ConclusionsComparison with controls and the timing of events do not indicate a causal relationship between SIB and brodalumab treatment.